Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ABBV AbbVie Earnings and EPS analysis

EPS in 2025 (TTM): $2.36

Last Report Period Date: Mar 31, 2025

As of May this year, based on AbbVie's most recent financial report, the company's trailing twelve months EPS is $2.36. During 2024, ABBV reported a per-share earnings of $2.4, which shows a decline compared to the EPS of $2.73 recorded in 2023. AbbVie's EPS for the quarterly period ending on Mar 31, 2025 came in at $0.72.

ABBV earnings history

Historical annual and quarterly earnings per share (EPS) data for AbbVie
EPS (TTM)
$2.36
EPS Growth YoY (Quarterly)
-6.5%
EPS (Quarterly)
$0.72
EPS Growth (Quarterly)
7,300%

The yearly earnings per share during 2024 was $2.4, a decline of 12.1% compared to $2.73 recorded in 2023. Over the quarter ending Mar 31, 2025, the earnings per share came in at $0.72, reflecting a 6.5% decline compared to the same quarter a year earlier. As of March 2025, the TTM EPS is $2.36. During 2023, the annual earnings per share was $2.73, representing a decrease of 58.9% compared to 2022.

ABBV EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-6.5%
EPS growth YoY
-12.1%
EPS growth 3Y avg
-28.2%
EPS growth 5Y avg
-14.7%

AbbVie has recorded a decline in earnings per share of 6.5% in the past 12 months (YoY, quarterly). During the past three years, ABBV registered an average yearly EPS growth of -28.2%. AbbVie had an average annual EPS growth of -14.7% in the last five years. Over the last decade, ABBV had an average annual earnings per share growth of 8%.

ABBV Earnings Waterfall

Breakdown of revenue, profit and net income for AbbVie

ABBV Earnings vs Peers

What are the earnings of ABBV compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BIIB Biogen Inc 12.77 39.8% 2.4% -18.7%
PFE Pfizer Inc 16.9 273.7% -28.7% -13.2%
BMY Bristol Myers Squibb Co 18.01 -213.7% N/A N/A
GILD Gilead Sciences Inc 23.08 -91.6% -57.5% -38.3%
AMGN Amgen Inc 26.08 -39.3% -9.7% -10.1%
AZN Astrazeneca plc 29.02 18.2% 284.3% 34.3%
NBIX Neurocrine Biosciences Inc 40.6 32.8% 53% 53.4%
LLY ELI LILLY & Co 59.78 102.1% 24.1% 5.7%
ABBV AbbVie Inc 78.86 -12.1% -28.2% -14.7%

All data is based on quarterly TTM periods, unless otherwise specified.